Siafil (Sildenafil) is commonly used across two distinct therapeutic domains, both providing targeted support for conditions characterized by specific circulatory issues. The medicine is applied to help manage symptoms related to functional strain and distress. This medicine is relevant in clinical settings requiring supportive symptom management for both sexual health and cardiopulmonary function.

The medication is commonly used across conditions presenting with episodic or fluctuating manifestations, including Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). It is generally applied in situations involving distressing symptoms that create noticeable physiological strain.

Supporting Functional Rigidity and Sexual Health

This application addresses the symptomatic inability to achieve or sustain a penile erection firm enough for satisfactory sexual activity. It helps adult men manage the interference that functional sexual impotence places on their sexual health and intimate relationships. It is relevant for managing symptoms that interfere with daily comfort.

Management of Pulmonary Arterial Hypertension (PAH) Symptoms

Siafil is also considered relevant in conditions marked by increased physiological stress, specifically PAH. It is applied in managing symptom clusters like shortness of breath and tiredness, which arise from high blood pressure in the lung arteries. The medicine contributes to improved exercise tolerance and may assist with maintaining physical capacity, supporting general well-being during symptomatic phases.

Quick Fact: Relief for Functional Impairment Siafil is used to provide symptomatic support that supports the process of maintaining functional stability, whether for supporting the achievement of adequate penile rigidity or for increasing physical capacity in patients with compromised cardiopulmonary function.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Siafil — official regulatory information

Siafil (tadalafil) is generally intended for adult males (18 years and older). Official regulatory labeling specifies strict exclusions and requires special medical consideration for several groups to ensure safe use.

Populations for whom use is Contraindicated

Use is strictly prohibited for patients taking any form of organic nitrate (e.g., nitroglycerin) or a guanylate cyclase stimulator (e.g., riociguat) due to the risk of a dangerous drop in blood pressure. The medicine is also contraindicated for patients with a known severe hypersensitivity to tadalafil or any tablet component.

Populations for whom use is Not Recommended or Restricted

For those with mild or moderate hepatic or renal impairment, dosage adjustments or caution are required. There is no standard recommendation for use during pregnancy or lactation for this medicine.

Siafil (tadalafil) may interact with certain medications and substances, potentially causing serious health risks, particularly a severe drop in blood pressure (hypotension).

It is essential to inform your healthcare provider about all prescription, over-the-counter, and herbal products you are taking.

Additionally, consuming grapefruit or grapefruit juice may increase the concentration of Siafil in the blood, increasing the risk of side effects. Large amounts of alcohol should be avoided as it can intensify the blood pressure-lowering effects of Siafil.

Siafil's mechanism is defined by its selective action as a competitive inhibitor of the enzyme Phosphodiesterase type 5 (PDE5). This enzyme is primarily localized in the smooth muscle cells of certain vascular beds. The drug's molecular interaction with PDE5 prevents the breakdown of its substrate, cyclic Guanosine Monophosphate (cGMP). By blocking this hydrolysis, Siafil prolongs the action of cGMP. The resulting accumulation of cGMP is critical, as it enhances the effects of the naturally occurring Nitric Oxide (NO) signaling pathway. This augmentation initiates an intracellular cascade that decreases the concentration of intracellular calcium ( Ca^2+) ions, thereby reducing vascular tone in targeted arteries. The molecular and cellular processes culminate in the relaxation of specific arterial smooth muscle, leading to vasodilation and a decrease in vascular resistance. This physiological modulation results in the core localized hemodynamic effect of the medication: an increase in blood flow to the targeted area.

Siafil is administered using specific protocols that are defined by the indications—either Erectile Dysfunction (ED) or Pulmonary Arterial Hypertension (PAH). The administration guidelines mandate distinct dosing schedules, routes, and constraints.

Official Administration Routes and Forms

Sildenafil, the active ingredient in Siafil, is available for oral intake as film-coated tablets (e.g., 25 mg to 100 mg for ED, and 20 mg for PAH) and as an oral suspension. It is also available as an intravenous (IV) injection (10 mg bolus) reserved exclusively for the PAH indication.

Indication-Specific Dosing and Timing

The usage pattern depends on the purpose. For ED, the medicine is taken as needed, typically 30 minutes to 4 hours before sexual activity, with a maximum dose of 100 mg allowed once per day. The timing is flexible and may be taken with or without food.

For PAH, the medicine follows a fixed schedule of three times a day (TID), often at a 20 mg dose, and is intended for long-term chronic management. Doses are generally spaced 6 to 8 hours apart.

Population and Procedural Constraints

Dose adjustments are required for specific patient groups. For older adults (65 years and up) and individuals with severe renal or hepatic impairment, a lower 25 mg starting dose for the ED regimen should be considered. Furthermore, when the medicine is co-administered with certain strong enzyme inhibitors (like ritonavir), the maximum dose for ED must not exceed 25 mg within a 48-hour period. The oral suspension formulation requires reconstitution with water before use and must be shaken well prior to each dose.

Research Evidence / Overview of Studies for Siafil

The research exploring the medicine in conditions marked by functional limitations related to Erectile Dysfunction (ED) relies on numerous clinical studies. The evidence base primarily consists of many randomized, placebo-controlled trials (RCTs). These studies were designed to examine short-term symptom patterns by monitoring patient-reported outcomes describing perceived discomfort and changes over a period of several weeks. Research explored how symptoms evolved in the observed populations across different causes of ED. Findings describe patterns observed in the studies where functional measurements were assessed during the study period. However, research does not provide individual predictions of measured outcomes.

Research Evidence for Use in Pulmonary Arterial Hypertension (PAH)

The research exploring Siafil in PAH, a condition marked by high physiological strain in the lung arteries, involved specialized multi-center, placebo-controlled RCTs. These studies were applied in research contexts involving fluctuating or unstable symptoms related to breathing and physical capacity. The main focus of these trials was to examine functional measures, with studies monitoring outcomes related to daily functioning or activity level. The core measure was the 6-Minute Walk Distance (6MWD), a functional outcome metric. Research reports on the functional capacity of the observed populations, measured via the 6MWD. Studies examined measurements related to the time to clinical worsening events (like hospitalization or need for other interventions).

Study Quality, Consistency, and Gaps

The evidence base is generally supported by the use of RCTs for the two main indications. However, certain limitations and uncertainties exist. For PAH, sample sizes were modest in some primary studies because it is a relatively rare condition. This limits the generalizability of the research findings to all potential patient subgroups. Additionally, comparative evidence is lacking for both indications, meaning there are few head-to-head studies comparing Siafil directly against other treatments in a controlled trial setting. Long-term effects are not fully established or well-characterized across many years, as the core efficacy trials had limited follow-up durations.

Key Studies & References

1. Sildenafil: MedlinePlus Drug Information

Common questions about Siafil (FAQ)

Q: Is Siafil considered a long-acting medicine compared to similar drugs?

According to the official product information, the terminal half-life of the active ingredient is approximately 4 hours, which relates to the duration of its presence in the body. However, official regulatory labels generally do not provide direct comparisons of duration or effectiveness against other medicines in the same class.

Q: What is the maximum duration of action for Siafil?

Studies and official information indicate that for the Erectile Dysfunction (ED) indication, the therapeutic effect has been observed for up to 4 hours post-dose. It is important to note that the intensity of the response may be diminished at the 4-hour mark compared to the initial effect observed around 2 hours post-dose.

Q: Is it safe to take Siafil with high blood pressure medication?

Siafil is known to have vasodilatory properties, meaning it causes blood vessels to widen, which can result in mild and transient decreases in blood pressure. Regulatory documents state that the medicine should be used with caution when taken alongside other blood pressure-lowering drugs, notably a type known as alpha-blockers. Regulatory documents address the need for monitoring blood pressure when the medicine is co-administered with certain drugs.

Q: What is the official guidance on mixing Siafil and alcohol?

Official information indicates that consuming alcohol may increase the risk of hypotensive effects, which is a significant drop in blood pressure. This occurs because alcohol can intensify the drug's vasodilatory action.

Q: Can people with liver or kidney problems use Siafil?

Regulatory documents state that patients with severe renal (kidney) or hepatic (liver) impairment may have slower clearance, or removal, of the medicine from the body. Official guidelines indicate that specific starting doses or adjustments may be required due to this factor.

Q: Is Siafil use limited by a person's age?

Use is generally limited in pediatric patients (under 18 years old) except for the Pulmonary Arterial Hypertension (PAH) indication in certain regions, as described in regulatory documents. For older adults (65 years and up), official prescribing information notes that regulatory guidance addresses the need for adjustment in the starting dose.

Q: Does the effectiveness of Siafil decrease over time with regular use?

Official regulatory documents do not specifically address whether tolerance (decreased effectiveness) develops over time with regular use. However, the general safety profile of the active ingredient supports that it is safe for long-term use without causing lasting harmful effects.

Q: Are there any specific warnings for people with a history of heart issues?

The drug is strictly contraindicated for patients who are using any form of organic nitrate medication due to the risk of a dangerous drop in blood pressure. The drug is also restricted in certain populations with a history of recent heart issues (such as a heart attack or stroke within the last six months), requiring careful consideration by the prescriber.

Q: Is Siafil intended for continuous long-term use?

The intention for use differs by condition. The Erectile Dysfunction (ED) indication is for use 'as needed' before activity. Conversely, the Pulmonary Arterial Hypertension (PAH) indication is prescribed as a fixed-schedule regimen intended for long-term chronic management.

Q: Is Siafil effective for people who have diabetes?

Official information indicates that the clinical studies used to establish the effectiveness of the medicine for the Erectile Dysfunction indication included populations with various underlying causes. These populations included patients with conditions such as diabetes.

Q: Are there any known long-term side effects from regularly using Siafil?

Official regulatory documents detail all known adverse events based on clinical trials and post-marketing surveillance. While these documents list specific side effects, evidence indicates that the long-term effects spanning many years are noted as not fully established by the core efficacy trials, which had limited follow-up periods.

Q: Does Siafil interact with common pain relievers like ibuprofen?

Official information does not list all common pain relievers as specific major interactants. The official label emphasizes the importance of informing the prescriber of all medicines and supplements being taken.

Q: Are there any specific foods or drinks that should be avoided when taking Siafil?

Official documents note that the consumption of grapefruit or grapefruit juice may increase the concentration of the medicine in the blood. The interaction with grapefruit is subject to specific regulatory discussion, underscoring the importance of patient-prescriber communication.

Q: Is there a specific time of day recommended for taking daily Siafil?

For the chronic regimen used to treat Pulmonary Arterial Hypertension (PAH), the medicine is taken at approximately the same times every day according to a fixed schedule.

Q: Does taking Siafil with food change how quickly it works?

Official pharmacokinetic information indicates that taking it with a high-fat meal can reduce the rate of absorption. This effect causes the medicine to take longer to reach its maximum concentration in the blood compared to taking it on an empty stomach.

Q: Is Siafil available as a generic medicine?

The active ingredient in the medicine, sildenafil, is available from various manufacturers worldwide. According to general regulatory information, this active ingredient is available as a generic medicine.

Q: Are there different brand names for the medicine Siafil?

Yes, the active ingredient, sildenafil, is marketed under different brand names. These different proprietary names are often used for distinct formulations or to distinguish between the two approved conditions that the medicine treats.

Q: Does Siafil treat the underlying cause of a condition or only the symptoms?

The medicine is classified as a PDE5 inhibitor that acts by addressing a physiological mechanism. It promotes vasodilation (vessel widening) to enhance blood flow, which contributes to managing the symptoms of the conditions for which it is approved.

Q: What are the restrictions on Siafil use in women, if any?

Sildenafil is officially indicated for the treatment of Pulmonary Arterial Hypertension (PAH) in both men and women. Use during pregnancy or lactation is subject to specific regulatory considerations, as noted in official prescribing information.

Q: What should be done if Siafil does not work as expected?

Lack of efficacy is a factor that informs the prescribing decision; patients should communicate observed effects to their healthcare provider. Official guidance indicates that dosage may need to be adjusted based on the individual's response.

Q: What is the official guidance regarding missing a dose of daily Siafil?

Regulatory documents detail a specific protocol for the chronic regimen: the dose should be taken if remembered, but is to be skipped if nearly time for the next scheduled dose. The protocol strictly advises against taking a double dose to make up for a missed one.

Q: How is the potency of Siafil measured in clinical trials?

Efficacy in clinical trials is assessed using a combination of objective clinical measurements and patient-reported outcomes. Examples include objective tools to measure physical response (like RigiScan) and validated measures, such as the International Index of Erectile Function (IIEF) score.

Q: Can Siafil be taken with herbal supplements?

The official label emphasizes the importance of informing the prescriber of all substances being taken. This includes all prescription medicines, over-the-counter products, and any nutritional supplements or herbal products.

Q: Can Siafil be split or crushed to take a smaller amount?

The film-coated tablets are intended to be swallowed whole. Splitting or crushing the tablets may alter their intended absorption kinetics (how the medicine is taken up by the body). This action is not recommended unless a specific formulation is designed for it.

Q: What is the half-life of Siafil?

According to official pharmacokinetic data, the terminal half-life of the active ingredient (sildenafil) and its major active metabolite is approximately 4 hours.

How to Store and Dispose of Siafil (Sildenafil)

The storage and disposal requirements for Siafil (Sildenafil) tablets are strictly defined by regulatory labeling to ensure product stability and safety.

Storage Requirements

Sildenafil must be stored at controlled room temperature, maintaining a range between 20°C to 25°C (68°F to 77°F). The medication must be kept in its original container and be protected from moisture. It is mandatory to keep Siafil out of the sight and reach of children.

Disposal Instructions

Unused or expired tablets must not be disposed of via wastewater or household trash. Disposal must be carried out according to the local requirements for pharmaceutical waste, often through authorized take-back programs.